RBC Capital Bullish On Opus Genetics (IRD) Amid Limited Competition And De Risked Setup The stock market's perpetual dance between hype and reality has once again brought a small cap biotech into the spotlight, courtesy of RBC Capital's bullish call on Opus Genetics.
The company's shares have skyrocketed nearly 110% year to date, driven in part by analyst implied upside tied to upcoming clinical data readouts.
Opus Genetics is not an isolated case; rather, it represents one end of a spectrum in the biotech sector.